Kamada (Kamada) Capex-to-Operating-Income : 0.71 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Kamada Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Kamada's Capital Expenditure for the three months ended in Dec. 2023 was $-1.97 Mil. Its Operating Income for the three months ended in Dec. 2023 was $2.78 Mil.

Hence, Kamada's Capex-to-Operating-Income for the three months ended in Dec. 2023 was 0.71.

Kamada Capex-to-Operating-Income Historical Data

The historical data trend for Kamada's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada Capex-to-Operating-Income Chart

Kamada Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Get a 7-Day Free Trial

0.10

0.29

0.84

0.58

Kamada Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Capex-to-Operating-Income	Get a 7-Day Free Trial															0.24	3.87	0.40	0.40	0.71

Competitive Comparison of Kamada's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kamada's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Kamada's Capex-to-Operating-Income falls into.

Kamada Capex-to-Operating-Income Calculation

Kamada's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-5.85)	/	10.064
	=	0.58

Kamada's Capex-to-Operating-Income for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-1.974)	/	2.776
	=	0.71

Kamada (NAS:KMDA) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Kamada Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Kamada's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (Kamada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.